WORCESTER, Mass. and TORONTO, Sept. 12, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) today addressed the unusual high volume of trading in shares of its common stock on the Over-the-Counter Bulletin Board yesterday and today.
The trading did not involve any shares held by current Company officers, directors, insiders, or employees.
Generex management is not aware of any Company developments that might tend to precipitate the unusual and sudden trading activity seen over the last two days.
Next week, Generex management will address Company stockholders regarding the status of initiatives of the Company and its wholly-owned subsidiary, Antigen Express, Inc.
The Company expressly disclaims any obligation in the future to address in public announcements (or otherwise) unusual patterns of trading in its common stock or unusual prices or price swings thereof.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clea